Hjem › Leverkreft (hepatocellulært karcinom) › Ohio
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Ohio
23 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i Ohio.
Byer i Ohio
Offisiell studietekst (engelsk)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06995898Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #10, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07227012National Liver Cancer Screening Trial
- The Cleveland Clinic, Cleveland
RekruttererFase 4
Alder 18 til 85 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06084234A Study Evaluating a New Radiation Treatment Workflow (NGDS)
- University Hospital Cleveland Medical Center, Cleveland
Rekrutterer
Alder 21 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07824583Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Miami Valley Hospital South, Centerville
- Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
RekruttererObservasjonsstudie
Alder 22 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06486454Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Case Western Reserve University, Cleveland
- og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT07166406A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nationwide Children's Hospital, Colombus
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT05208762DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Cleveland Clinic, Cleveland
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 21. jul. 2026 · NCT07717437A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. jun. 2026 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Louis Stokes VA Medical Center, Cleveland, OH, Cleveland
Rekrutterer
Alder 18 til 75 · Alle kjønn · Oppdatert 17. jun. 2026 · NCT0548657268Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 8. mai 2026 · NCT06852820A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Cleveland Clinic Lerner College of Medicine, Cleveland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. apr. 2026 · NCT05440708Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alle aldre · Alle kjønn · Oppdatert 9. mar. 2026 · NCT04792463Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Cincinnati Children's Medical Center, Cincinnati
RekruttererFase 2
Alder 0 til 30 · Alle kjønn · Oppdatert 24. feb. 2026 · NCT04134559HOPE Against Cancer Recurrence in HCC
- Cleveland Clinic, Cleveland
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 16. des. 2025 · NCT06717919A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 138, Canton
- Research Site 113, Cincinnati
- Research Site 131, Dayton
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. nov. 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Cleveland Clinic, Cleveland
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 15. mai 2025 · NCT06914648A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. nov. 2024 · NCT05824975Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.